Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2019-08-20 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Morepen Laboratories Ltd has informed BSE regarding Issuance of Duplicate Share Certificates of the Company.
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates due to loss of original certificates. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs share certificate issuance and related disclosures. The content is about share certificate replacement and does not contain financial statements, earnings data, management discussion, or any report publication. It is a regulatory announcement related to shareholding documentation and compliance rather than a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-08-20 English
AGM/Book Closure
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 123 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or filing type. Given the lack of content, the document best fits the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2019-08-19 English
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 34(1) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, ....
Annual Report Classification · 100% confidence The document is a detailed report from Morepen Laboratories Limited for the financial year ended March 31, 2019. It includes a Notice of the 34th Annual General Meeting (AGM), Directors' Report, financial highlights, audited financial statements, independent auditors' report, corporate governance report, and other annexures typically found in a comprehensive yearly report. The presence of consolidated and standalone financial statements, detailed financial performance analysis, and statutory auditor reports confirms this is the full Annual Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K).
2019-08-19 English
Pursuant to the provisions of Section 91 of Companies Act, 2013 read with Rule 10 of the Companies (Management and Administration) Rules, 2014 and Regulation 42 of SEBI (Listing Obligations ....
AGM Information Classification · 95% confidence The document is a notice addressed to stock exchanges regarding the 34th Annual General Meeting (AGM) of Morepen Laboratories Limited. It includes details about the AGM date, venue, book closure dates, and voting procedures. It mentions the Annual Report for the financial year 2018-19 is enclosed but does not contain the report itself or detailed financial data. The document is primarily an announcement about the AGM and related administrative details, not the report or presentation materials shared at the AGM. Therefore, it fits best under AGM Information (AGM-R) as it relates to the AGM notice and associated information.
2019-08-19 English
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed ....
AGM Information Classification · 100% confidence The document is a detailed notice for the 34th Annual General Meeting (AGM) of Morepen Laboratories Limited, scheduled for September 13, 2019. It includes agenda items such as adoption of audited financial statements for the fiscal year ended March 31, 2019, appointment and re-appointment of directors, approval of remuneration, and other special resolutions related to company governance and financial authorizations. The presence of the term 'NOTICE' and the detailed agenda for the AGM, including resolutions to be passed, clearly identifies this document as materials shared for the Annual General Meeting. It is not the annual report itself, nor a voting result announcement, but the official notice of the AGM meeting and its agenda. Therefore, the correct classification is AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is not a brief announcement or a certification but a full AGM notice.
2019-08-19 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated August 13, 2019, reporting the financial performance of Morepen Laboratories Limited for the quarter ended June 30, 2019 (Q1 FY 2019-20). It contains detailed financial highlights such as net sales revenue, net profit after tax, EBITDA, cash profit, and segment-wise sales growth. The document also discusses operational achievements like USFDA approvals, export growth, and R&D accreditation. The content is focused on quarterly financial results and business updates rather than a full comprehensive report. It is not a full interim or quarterly report with detailed financial statements but rather a press release summarizing key financial results and business highlights for the quarter. Therefore, the document fits best into the Earnings Release (ER) category, which is defined as the initial announcement of quarterly/periodical financial results with key highlights only. The document length (over 14,000 characters) and detailed financial data support this classification with high confidence. Q1 2020
2019-08-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.